요로감염증 시장 : 치료법, 진단 방법, 감염증 유형, 연령층, 감염 부위, 투여 경로, 병원체 유형, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Urinary Tract Infection Market is projected to grow by USD 16.62 billion at a CAGR of 7.15% by 2032.

Urinary tract infection (UTI) remains one of the most common bacterial infections across community, outpatient, long-term care, and hospital settings. Clinical literature consistently identifies Escherichia coli as the leading cause of uncomplicated UTI, while recurrent UTI, catheter-associated UTI (CAUTI), pregnancy-related UTI, diabetes-associated UTI, and infections in older adults increase diagnostic and therapeutic complexity.

The UTI industry landscape is shaped by high patient volumes, rising antimicrobial resistance, demand for rapid UTI diagnostics, expanded telehealth triage, and renewed interest in non-antibiotic UTI prevention. Industry leaders are prioritizing stewardship-aligned antibiotics, point-of-care testing, molecular diagnostics, vaccine research, microbiome-based approaches, and digital care pathways that reduce avoidable prescribing while improving patient outcomes.

Transformative Shifts in the UTI Landscape

The urinary tract infection landscape is shifting from empiric treatment toward evidence-based, risk-stratified care. Antimicrobial resistance is the strongest catalyst: surveillance programs in the United States, Europe, and Asia report increasing resistance among uropathogens, especially fluoroquinolone resistance and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. This is accelerating demand for culture-guided therapy, local antibiogram integration, and rapid antimicrobial susceptibility testing.

Care delivery is also transforming. Retail clinics, telemedicine platforms, and home-based sample collection are expanding access for uncomplicated UTI, while hospitals focus on CAUTI prevention bundles, catheter-use reduction, and infection-control analytics. At the same time, women's health investment, aging demographics, diabetes prevalence, and the burden of recurrent UTI are creating demand for preventive solutions beyond traditional antibiotics.

Cumulative Impact of Artificial Intelligence on UTI Care

Artificial intelligence is becoming a practical enabler across the UTI value chain. In diagnostics, AI-supported urinalysis interpretation, image-based microscopy, and machine learning models can help flag contaminated samples, predict culture positivity, and prioritize specimens for confirmatory testing. In clinical decision support, algorithms can incorporate symptoms, pregnancy status, renal function, prior cultures, allergies, and local resistance patterns to support stewardship-aligned prescribing.

AI is also influencing drug discovery and population health. Predictive models can identify patients at higher risk of recurrent UTI or CAUTI, while hospital analytics can monitor catheter days, adherence to prevention bundles, and antibiotic utilization. The greatest commercial impact will come from validated AI tools that demonstrate clinical utility, interoperability with electronic health records, transparent performance across populations, and compliance with medical device and data privacy regulations.

Key Regional Insights Across the UTI Market

North America benefits from mature diagnostic infrastructure, strong antimicrobial stewardship programs, and high adoption of telehealth for uncomplicated UTI management, with U.S. and Canadian public health agencies continuing to emphasize appropriate antibiotic use and healthcare-associated infection prevention. Europe is shaped by national antibiotic stewardship policies, European Association of Urology guidance, coordinated antimicrobial resistance surveillance, and widespread emphasis on reducing inappropriate antibiotic exposure. Asia-Pacific is expanding access to UTI diagnosis and care through large patient populations, rising healthcare utilization, and increasing investments in clinical laboratories, though uneven access to urine culture testing and variable antibiotic use remain persistent challenges.

Latin America is seeing greater demand for affordable UTI diagnostics and standardized treatment pathways as public and private healthcare systems address resistance and recurrent infection burden, particularly in urban centers with expanding laboratory networks. The Middle East is strengthening tertiary-care capacity and infection prevention programs, especially in advanced hospital networks across the region where CAUTI prevention, stewardship, and digital health modernization are policy priorities. Africa faces the dual challenge of underdiagnosis and limited laboratory access in many settings, creating opportunities for low-cost point-of-care diagnostics, surveillance expansion, antimicrobial stewardship education, and practical care pathways suited to resource-variable environments.

Key Group Insights for UTI Market Growth

Within ASEAN, UTI demand is influenced by expanding primary care access, urbanization, rising chronic disease burden, and the need for cost-effective diagnostics that can operate in both centralized laboratories and decentralized care settings. The GCC is characterized by high healthcare investment, advanced hospital systems, and growing attention to antimicrobial stewardship, particularly for complicated UTI, CAUTI management, and infection-control performance across tertiary facilities. The European Union remains a benchmark for coordinated antimicrobial resistance surveillance, regulatory rigor, stewardship-driven prescribing, and guideline-based UTI management.

BRICS countries represent large-volume opportunities driven by population scale, rising diabetes and aging-related risk factors, and expanding diagnostic capacity, but they also face significant resistance-management challenges that require improved surveillance and rational prescribing. G7 markets are differentiated by higher adoption of molecular diagnostics, digital health tools, robust laboratory quality systems, and regulated clinical pathways for outpatient and hospital-based UTI care. NATO-aligned healthcare systems, while diverse, generally emphasize health security, resilient medical supply chains, and preparedness against antimicrobial resistance as a strategic public health threat affecting infection management.

Key Country Insights in the UTI Market

The United States has strong demand for telehealth-enabled UTI care, rapid diagnostics, and CAUTI reduction programs, supported by CDC antimicrobial stewardship initiatives and hospital quality reporting. Canada emphasizes prudent antibiotic use, primary care access, and surveillance, while Mexico and Brazil show opportunities for affordable diagnostics, standardized prescribing, and expanded laboratory capacity as healthcare systems address recurrent UTI and antimicrobial resistance. In the United Kingdom, national guidance and antimicrobial stewardship strongly influence prescribing behavior, while Germany and France combine advanced diagnostics with structured healthcare reimbursement, laboratory networks, and surveillance systems.

Italy and Spain face meaningful recurrent UTI and older-adult care needs, reinforcing demand for prevention strategies and rapid testing. Russia's market is influenced by large population needs, infectious disease surveillance priorities, and evolving access to modern diagnostics. China and India carry substantial UTI volumes and rising resistance concerns, making scalable diagnostics, urine culture access, and stewardship essential for both outpatient and inpatient settings. Japan, South Korea, and Australia have advanced healthcare infrastructure, strong diagnostic quality expectations, and growing interest in prevention strategies for aging populations, recurrent UTI patients, and catheter-associated infection reduction.

Actionable Recommendations for UTI Industry Leaders

Industry leaders should align product strategy with antimicrobial stewardship by prioritizing diagnostics and therapeutics that reduce unnecessary antibiotic exposure and support targeted treatment. Companies should invest in rapid susceptibility testing, molecular panels for complicated UTI, and digital clinical decision support that integrates with electronic health records, laboratory information systems, and local resistance data.

Manufacturers and service providers should segment the UTI market by care setting: telehealth and retail care for uncomplicated UTI, hospital systems for CAUTI prevention and complicated infection, and specialist care for recurrent UTI. Partnerships with laboratories, women's health platforms, payers, public health stakeholders, and health systems can accelerate adoption when solutions demonstrate reduced time to appropriate therapy, fewer repeat visits, lower hospitalization risk, improved patient adherence, and measurable stewardship value.

Research Methodology

This executive summary is based on secondary research from peer-reviewed clinical literature, public health agencies, regulatory guidance, and recognized professional organizations, including CDC, WHO, NIH, IDSA, EAU, national antimicrobial resistance surveillance programs, and published infection-control evidence. The analysis prioritizes validated epidemiology, clinical practice trends, diagnostics adoption, antimicrobial resistance patterns, healthcare-associated infection prevention, and regional healthcare infrastructure indicators.

Insights were synthesized through cross-comparison of guideline updates, surveillance findings, hospital infection-prevention priorities, and technology adoption signals. Market interpretation focuses on evidence-backed drivers rather than unsupported projections, with emphasis on clinical utility, regulatory readiness, reimbursement feasibility, interoperability, stewardship alignment, and operational adoption across outpatient, inpatient, and long-term care environments.

Conclusion

The urinary tract infection market is entering a more precision-oriented phase as antimicrobial resistance, recurrent infection burden, and healthcare access pressures reshape demand. Growth will increasingly favor solutions that improve diagnostic certainty, shorten time to appropriate therapy, prevent catheter-associated infections, and reduce unnecessary antibiotic use.

Organizations that combine validated UTI diagnostics, AI-enabled workflows, stewardship-aligned therapeutics, and patient-centered care models will be best positioned to lead. The strongest opportunities will emerge where clinical evidence, affordability, interoperability, and regional implementation needs are addressed together.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urinary Tract Infection Market, by Treatment

• 7.1. Antibiotics
  • 7.1.1. Fosfomycin
  • 7.1.2. Nitrofurantoin
  • 7.1.3. Trimethoprim/Sulfamethoxazole
  • 7.1.4. Penicillins
  • 7.1.5. Cephalosporins
  • 7.1.6. Fluoroquinolones
• 7.2. Non Antibiotic Therapies
  • 7.2.1. D-mannose
  • 7.2.2. Probiotics
  • 7.2.3. Immunomodulatory Supplements

8. Urinary Tract Infection Market, by Diagnosis Method

• 8.1. Urinalysis
• 8.2. Urine Culture
• 8.3. Dipstick Tests
• 8.4. Molecular Diagnostics
• 8.5. Point-of-Care Testing

9. Urinary Tract Infection Market, by Infection Type

• 9.1. Uncomplicated Cystitis
• 9.2. Complicated Urinary Tract Infection
• 9.3. Pyelonephritis
• 9.4. Recurrent Urinary Tract Infection
• 9.5. Catheter-Associated Urinary Tract Infection
• 9.6. Asymptomatic Bacteriuria

10. Urinary Tract Infection Market, by Age Group

• 10.1. Adults
• 10.2. Geriatrics
• 10.3. Pediatrics

11. Urinary Tract Infection Market, by Infection Site

• 11.1. Lower Tract Infection
  • 11.1.1. Cystitis
  • 11.1.2. Urethritis
• 11.2. Upper Tract Infection
  • 11.2.1. Pyelonephritis
  • 11.2.2. Ureteritis

12. Urinary Tract Infection Market, by Route Of Administration

• 12.1. Oral Route
• 12.2. Intravenous Route
• 12.3. Intramuscular Route
• 12.4. Intravesical Route

13. Urinary Tract Infection Market, by Pathogen Type

• 13.1. Bacterial Pathogens
  • 13.1.1. Escherichia Coli
  • 13.1.2. Klebsiella Species
  • 13.1.3. Proteus Species
  • 13.1.4. Pseudomonas Aeruginosa
  • 13.1.5. Enterococcus Species
  • 13.1.6. Staphylococcus Saprophyticus
• 13.2. Fungal Pathogens
• 13.3. Viral Pathogens
• 13.4. Parasitic Pathogens

14. Urinary Tract Infection Market, by End User

• 14.1. Clinics & Outpatient Centers
• 14.2. Homecare Settings
• 14.3. Hospitals
• 14.4. Diagnostic Laboratories
• 14.5. Long-Term Care Facilities

15. Urinary Tract Infection Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Urinary Tract Infection Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Urinary Tract Infection Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AbbVie Inc.
• 19.2. Almirall, SA
• 19.3. Aspen Pharmacare Holdings Limited
• 19.4. AstraZeneca PLC
• 19.5. Bayer AG
• 19.6. Beckman Coulter, Inc.
• 19.7. Boehringer Ingelheim International GmbH
• 19.8. Bristol-Myers Squibb Company
• 19.9. Cipla Limited
• 19.10. Dr Reddys Laboratories Ltd.
• 19.11. Eli Lilly and Company
• 19.12. F Hoffmann-La Roche AG
• 19.13. GlaxoSmithKline PLC
• 19.14. Johnson & Johnson Services, Inc.
• 19.15. Lupin Ltd.
• 19.16. Merck & Co Inc.
• 19.17. Novartis AG
• 19.18. Novo Nordisk A/S
• 19.19. Pfizer Inc.
• 19.20. PhenUtest Diagnostics Ltd.
• 19.21. Randox Laboratories Ltd.
• 19.22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• 19.23. Shionogi & Co, Ltd.
• 19.24. Siemens Healthineers AG
• 19.25. Sun Pharmaceutical Industries Limited
• 19.26. Sysmex Corporation
• 19.27. Teva Pharmaceutical Industries Ltd.
• 19.28. URIT Medical Electronic Co., Ltd.
• 19.29. Viatris Inc